Aclaris Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
Aclaris Therapeutics, Inc. (ACRS) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 4.79 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-08-06
- Aclaris Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-06-30 was 467.25K shares, a 41.21% decline year-over-year.
- Aclaris Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-03-31 was 4.32M shares, a 11.91% increase year-over-year.
- Aclaris Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-12-31 was 213.15K shares, a 65.95% decline year-over-year.
- Aclaris Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-09-30 was 540.66K shares.
- Aclaris Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 5.41M shares, a 107.28% increase from fiscal 2024.
- Aclaris Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 2.61M shares, a 16.38% increase from fiscal 2023.
- Aclaris Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 2.24M shares, a 12.05% decline from fiscal 2022.
- Aclaris Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2022 was 2.55M shares, a 138.62% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|
| 2026-06-30 | 467.25K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | 4.79M shares 10-Q · filed 2026-08-06 | 5.00M shares derived: sum of 3 quarters · filed 2026-08-06 | 5.54M shares derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | 4.32M shares 10-Q · filed 2026-05-07 | 4.53M shares derived: sum of 2 quarters · filed 2026-05-07 | 5.07M shares derived: sum of 3 quarters · filed 2026-05-07 | 5.87M shares derived: sum of 4 quarters · filed 2026-05-07 |
| 2025-12-31 | 213.15K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | 753.81K shares derived: sum of 2 quarters · filed 2026-02-26 | 1.55M shares derived: sum of 3 quarters · filed 2026-02-26 | 5.41M shares 10-K · filed 2026-02-26 |
| 2025-09-30 | 540.66K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | 1.34M shares derived: sum of 2 quarters · filed 2025-11-06 | 5.19M shares 10-Q · filed 2025-11-06 | 5.82M shares derived: sum of 4 quarters · filed 2026-02-26 |
| 2025-06-30 | 794.76K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | 4.65M shares 10-Q · filed 2025-08-07 | 5.28M shares derived: sum of 3 quarters · filed 2026-02-26 | 5.28M shares derived: sum of 4 quarters · filed 2026-02-26 |
| 2025-03-31 | 3.86M shares 10-Q · filed 2025-05-08 | 4.48M shares derived: sum of 2 quarters · filed 2026-02-26 | 4.48M shares derived: sum of 3 quarters · filed 2026-02-26 | 4.63M shares derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-12-31 | 626.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | 626.00K shares derived: sum of 2 quarters · filed 2026-02-26 | 766.40K shares derived: sum of 3 quarters · filed 2026-02-26 | 2.61M shares 10-K · filed 2026-02-26 |
| 2024-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | 140.40K shares derived: sum of 2 quarters · filed 2024-11-06 | 1.98M shares 10-Q · filed 2024-11-06 | 2.01M shares derived: sum of 4 quarters · filed 2025-02-27 |
| 2024-06-30 | 140.40K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | 1.98M shares 10-Q · filed 2024-08-07 | 2.01M shares derived: sum of 3 quarters · filed 2025-02-27 | 2.15M shares derived: sum of 4 quarters · filed 2025-02-27 |
| 2024-03-31 | 1.84M shares 10-Q · filed 2024-05-07 | 1.87M shares derived: sum of 2 quarters · filed 2025-02-27 | 2.01M shares derived: sum of 3 quarters · filed 2025-02-27 | 2.18M shares derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-12-31 | 23.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | 167.00K shares derived: sum of 2 quarters · filed 2025-02-27 | 339.75K shares derived: sum of 3 quarters · filed 2025-02-27 | 2.24M shares 10-K · filed 2025-02-27 |
| 2023-09-30 | 144.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | 316.75K shares derived: sum of 2 quarters · filed 2023-11-06 | 2.22M shares 10-Q · filed 2023-11-06 | 2.43M shares derived: sum of 4 quarters · filed 2024-02-27 |
| 2023-06-30 | 172.75K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | 2.07M shares 10-Q · filed 2023-08-07 | 2.29M shares derived: sum of 3 quarters · filed 2024-02-27 | 2.73M shares derived: sum of 4 quarters · filed 2024-02-27 |
| 2023-03-31 | 1.90M shares 10-Q · filed 2023-05-08 | 2.12M shares derived: sum of 2 quarters · filed 2024-02-27 | 2.56M shares derived: sum of 3 quarters · filed 2024-02-27 | 2.99M shares derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-12-31 | 214.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | 656.80K shares derived: sum of 2 quarters · filed 2024-02-27 | 1.09M shares derived: sum of 3 quarters · filed 2024-02-27 | 2.55M shares 10-K · filed 2024-02-27 |
| 2022-09-30 | 442.80K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | 875.15K shares derived: sum of 2 quarters · filed 2022-11-08 | 2.33M shares 10-Q · filed 2022-11-08 | 2.39M shares derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | 432.35K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | 1.89M shares 10-Q · filed 2022-08-03 | 1.95M shares derived: sum of 3 quarters · filed 2024-02-27 | 1.97M shares derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | 1.46M shares 10-Q · filed 2022-05-10 | 1.51M shares derived: sum of 2 quarters · filed 2024-02-27 | 1.53M shares derived: sum of 3 quarters · filed 2024-02-27 | 1.65M shares derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | 54.50K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | 74.50K shares derived: sum of 2 quarters · filed 2024-02-27 | 187.50K shares derived: sum of 3 quarters · filed 2024-02-27 | 1.07M shares 10-K · filed 2024-02-27 |
| 2021-09-30 | 20.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-02 | 133.00K shares derived: sum of 2 quarters · filed 2021-11-02 | 1.01M shares 10-Q · filed 2021-11-02 | 1.01M shares derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-06-30 | 113.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | 993.60K shares 10-Q · filed 2021-08-05 | 993.60K shares derived: sum of 3 quarters · filed 2023-02-23 | 993.60K shares derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-03-31 | 880.60K shares 10-Q · filed 2021-05-07 | 880.60K shares derived: sum of 2 quarters · filed 2023-02-23 | 880.60K shares derived: sum of 3 quarters · filed 2023-02-23 | 1.01M shares derived: sum of 4 quarters · filed 2023-02-23 |
| 2020-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | 0.00 shares derived: sum of 2 quarters · filed 2023-02-23 | 132.00K shares derived: sum of 3 quarters · filed 2023-02-23 | 734.80K shares 10-K · filed 2023-02-23 |
| 2020-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-04 | 132.00K shares derived: sum of 2 quarters · filed 2020-11-04 | 734.80K shares 10-Q · filed 2020-11-04 | 734.80K shares derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-06-30 | 132.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-07 | 734.80K shares 10-Q · filed 2020-08-07 | 734.80K shares derived: sum of 3 quarters · filed 2022-02-24 | 750.80K shares derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-03-31 | 602.80K shares 10-Q · filed 2020-05-07 | 602.80K shares derived: sum of 2 quarters · filed 2022-02-24 | 618.80K shares derived: sum of 3 quarters · filed 2022-02-24 | 618.80K shares derived: sum of 4 quarters · filed 2022-02-24 |
| 2019-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | 16.00K shares derived: sum of 2 quarters · filed 2022-02-24 | 16.00K shares derived: sum of 3 quarters · filed 2022-02-24 | 44.50K shares 10-K · filed 2022-02-24 |
| 2019-09-30 | 16.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | 16.00K shares derived: sum of 2 quarters · filed 2019-11-07 | 44.50K shares 10-Q · filed 2019-11-07 | 106.40K shares derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | 28.50K shares 10-Q · filed 2019-08-08 | 90.40K shares derived: sum of 3 quarters · filed 2021-02-25 | 273.30K shares derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-03-31 | 28.50K shares 10-Q · filed 2019-05-08 | 90.40K shares derived: sum of 2 quarters · filed 2021-02-25 | 273.30K shares derived: sum of 3 quarters · filed 2021-02-25 | 398.30K shares derived: sum of 4 quarters · filed 2021-02-25 |
| 2018-12-31 | 61.90K shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | 244.80K shares derived: sum of 2 quarters · filed 2021-02-25 | 369.80K shares derived: sum of 3 quarters · filed 2021-02-25 | 1.46M shares 10-K · filed 2021-02-25 |
| 2018-09-30 | 182.90K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | 307.90K shares derived: sum of 2 quarters · filed 2018-11-06 | 1.40M shares 10-Q · filed 2018-11-06 | 1.57M shares derived: sum of 4 quarters · filed 2020-02-25 |
| 2018-06-30 | 125.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-03 | 1.22M shares 10-Q · filed 2018-08-03 | 1.39M shares derived: sum of 3 quarters · filed 2020-02-25 | 1.87M shares derived: sum of 4 quarters · filed 2020-02-25 |
| 2018-03-31 | 1.09M shares 10-Q · filed 2018-05-08 | 1.26M shares derived: sum of 2 quarters · filed 2020-02-25 | 1.75M shares derived: sum of 3 quarters · filed 2020-02-25 | 1.86M shares derived: sum of 4 quarters · filed 2020-02-25 |
| 2017-12-31 | 172.60K shares derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25 | 655.10K shares derived: sum of 2 quarters · filed 2020-02-25 | 774.10K shares derived: sum of 3 quarters · filed 2020-02-25 | 790.10K shares 10-K · filed 2020-02-25 |
| 2017-09-30 | 482.50K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | 601.50K shares derived: sum of 2 quarters · filed 2017-11-07 | 617.50K shares 10-Q · filed 2017-11-07 | 1.48M shares derived: sum of 4 quarters · filed 2019-03-18 |
| 2017-06-30 | 119.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-08 | 135.00K shares 10-Q · filed 2017-08-08 | 996.39K shares derived: sum of 3 quarters · filed 2019-03-18 | 1.04M shares derived: sum of 4 quarters · filed 2019-03-18 |
| 2017-03-31 | 16.00K shares 10-Q · filed 2017-05-09 | 877.39K shares derived: sum of 2 quarters · filed 2019-03-18 | 917.39K shares derived: sum of 3 quarters · filed 2019-03-18 | 1.03M shares derived: sum of 4 quarters · filed 2019-03-18 |
| 2016-12-31 | 861.39K shares derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-18 | 901.39K shares derived: sum of 2 quarters · filed 2019-03-18 | 1.02M shares derived: sum of 3 quarters · filed 2019-03-18 | 1.08M shares 10-K · filed 2019-03-18 |
| 2016-09-30 | 40.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-03 | 154.03K shares derived: sum of 2 quarters · filed 2016-11-03 | 222.53K shares 10-Q · filed 2016-11-03 | |
| 2016-06-30 | 114.03K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-11 | 182.53K shares 10-Q · filed 2016-08-11 | ||
| 2016-03-31 | 68.50K shares 10-Q · filed 2016-05-11 | |||
| 2015-12-31 | 1.24M shares 10-K · filed 2018-03-12 | |||
| 2015-06-30 | 0.00 shares 10-Q · filed 2016-08-11 | |||
| 2014-12-31 | 500.26K shares 10-K · filed 2017-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |